MCID: ALK015
MIFTS: 43

Alk-Positive Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Positive Anaplastic Large Cell Lymphoma:

Name: Alk-Positive Anaplastic Large Cell Lymphoma 59
Anaplastic Large Cell Lymphoma, Alk Negative 73
Anaplastic Large Cell Lymphoma, Alk-Positive 73
Alk+ Anaplastic Large Cell Lymphoma 59
Alk+ Alcl 59

Characteristics:

Orphanet epidemiological data:

59
alk-positive anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood;

Classifications:



External Ids:

Orphanet 59 ORPHA300895
ICD10 via Orphanet 34 C84.6
ICD10 33 C84.6

Summaries for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Positive Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk negative, is related to alk-negative anaplastic large cell lymphoma and anaplastic large cell lymphoma. An important gene associated with Alk-Positive Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Glioma. The drugs Etoposide and Crizotinib have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and breast, and related phenotypes are endocrine/exocrine gland and integument

Related Diseases for Alk-Positive Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 alk-negative anaplastic large cell lymphoma 32.2 ALK STAT3
2 anaplastic large cell lymphoma 30.6 ALK JAK3 MCL1 MUC1 NPM1 STAT3
3 lung cancer susceptibility 3 29.9 ALK MUC1 STAT3
4 lymphoma 11.2
5 hemophagocytic lymphohistiocytosis 10.3
6 leukemia 10.3
7 leukemia, chronic lymphocytic 2 10.2
8 leukemia, chronic lymphocytic 10.2
9 neurofibromatosis, type i 10.2
10 b-cell lymphomas 10.2
11 lymphocytic leukemia 10.2
12 adenocarcinoma 10.2
13 inflammatory breast carcinoma 10.2
14 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.2
15 myeloid leukemia 10.2
16 leukemia, b-cell, chronic 10.2
17 tetraploidy 10.2
18 hypoxia 10.2
19 intravascular large b-cell lymphoma 10.2
20 peripheral t-cell lymphoma 10.1
21 lymphomatoid papulosis 10.1 ALK NPM1
22 lymphoma, hodgkin, classic 10.1
23 asthma 10.1
24 hematopoietic stem cell transplantation 10.1
25 pemphigus foliaceus 10.1
26 sarcoma 10.1
27 syphilis 10.1
28 soft tissue sarcoma 10.1
29 lymphatic system cancer 10.1 ALK NPM1
30 inflammatory myofibroblastic tumor 10.0 ALK NPM1
31 perineurioma 10.0 ALK MUC1
32 intraneural perineurioma 9.9 ALK MUC1
33 eccrine porocarcinoma 9.9 MUC1 STAT3
34 mucinous adenocarcinoma 9.9 ALK MUC1
35 myeloproliferative neoplasm 9.9 JAK3 STAT3
36 gastric tubular adenocarcinoma 9.9 MUC1 SHH
37 hematologic cancer 9.9 ALK MCL1 NPM1
38 lymphoma, non-hodgkin, familial 9.9 ALK MCL1 NPM1
39 respiratory system cancer 9.9 ALK STAT3
40 pneumothorax 9.9 ALK MUC1
41 brain cancer 9.9 ALK SHH STAT3
42 primary cutaneous anaplastic large cell lymphoma 9.8 ALK MUC1 NPM1
43 reticulosarcoma 9.8 ALK MUC1 NPM1
44 leukemia, acute myeloid 9.8 MCL1 NPM1 STAT3
45 pancreas adenocarcinoma 9.7 MUC1 SHH STAT3
46 cholangiocarcinoma 9.7 MCL1 MUC1 STAT3

Graphical network of the top 20 diseases related to Alk-Positive Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Positive Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Positive Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Alk-Positive Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.55 ALK JAK3 MCL1 SHH STAT3
2 integument MP:0010771 9.35 ALK MCL1 NPM1 SHH STAT3
3 neoplasm MP:0002006 8.92 ALK NPM1 SHH STAT3

Drugs & Therapeutics for Alk-Positive Anaplastic Large Cell Lymphoma

Drugs for Alk-Positive Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4,Phase 2 33419-42-0 36462
2
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
3 Etoposide phosphate Phase 4,Phase 2
4 Antineoplastic Agents, Phytogenic Phase 4,Phase 2
5 Protein Kinase Inhibitors Phase 4,Phase 1,Phase 2
6 Topoisomerase Inhibitors Phase 4,Phase 2
7
Ceritinib Approved Phase 1, Phase 2 1032900-25-6
8
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
9
alemtuzumab Approved, Investigational Phase 2 216503-57-0
10
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
11
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
12
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
13
Doxil Approved June 1999 Phase 2 31703
14 Immunologic Factors Phase 1, Phase 2,Phase 2
15 Antibodies, Monoclonal Phase 1, Phase 2
16 Immunoglobulins Phase 1, Phase 2
17 Antibodies Phase 1, Phase 2
18 Hormone Antagonists Phase 2
19 Immunosuppressive Agents Phase 2
20 Antineoplastic Agents, Alkylating Phase 2
21 glucocorticoids Phase 2
22 Anti-Inflammatory Agents Phase 2
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
24 Antineoplastic Agents, Hormonal Phase 2
25 Alkylating Agents Phase 2
26 Hormones Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Antimitotic Agents Phase 2
29 Anti-Bacterial Agents Phase 2
30 Antirheumatic Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
2 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
3 Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT03719898 Phase 2 Brigatinib
4 A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms Recruiting NCT03493451 Phase 2 BGB A317
5 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Active, not recruiting NCT00069238 Phase 2 EPOCH

Search NIH Clinical Center for Alk-Positive Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Positive Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Positive Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Positive Anaplastic Large Cell Lymphoma:

41
T Cells, Bone, Breast, Lung, Brain, B Cells, Myeloid

Publications for Alk-Positive Anaplastic Large Cell Lymphoma

Articles related to Alk-Positive Anaplastic Large Cell Lymphoma:

(show top 50) (show all 108)
# Title Authors Year
1
CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. ( 29512859 )
2018
2
Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/I^-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. ( 29609590 )
2018
3
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma. ( 29642597 )
2018
4
Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. ( 29030834 )
2018
5
Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report. ( 29952979 )
2018
6
Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib. ( 29622884 )
2018
7
ALK-positive anaplastic large-cell lymphoma with primary bone involvement: A rare case and review of the literature. ( 30173234 )
2018
8
CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. ( 30408331 )
2018
9
Minimal Change Disease as Initial Presentation of ALK-Positive Anaplastic Large-Cell Lymphoma in a Pediatric Patient. ( 29279700 )
2017
10
Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. ( 28665006 )
2017
11
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of ALK-Positive Anaplastic Large Cell Lymphoma. ( 28675026 )
2017
12
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman [Retraction]. ( 29296088 )
2017
13
ALK-positive anaplastic large cell lymphoma undiagnosed in a patient with tuberculosis: a case report and review of the literature. ( 28490385 )
2017
14
Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial. ( 28878445 )
2017
15
ALK positive Anaplastic Large Cell Lymphoma of the Thoracic Spine. ( 27761194 )
2016
16
Successful allogeneic bone marrow transplantation with reduced intensity conditioning regimen for a pediatric relapsed ALK positive anaplastic large cell lymphoma. ( 27498729 )
2016
17
ALK-positive anaplastic large-cell lymphoma with marked leukemoid reaction and hemophagocytic lymphohistiocytosis. ( 27563714 )
2016
18
Fine-needle aspiration cytology yield as a basis for morphological, molecular, and cytogenetic diagnosis in alk-positive anaplastic large cell lymphoma with atypical clinical presentation. ( 27468968 )
2016
19
ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy. ( 26834485 )
2016
20
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. ( 27795556 )
2016
21
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. ( 27793034 )
2016
22
A positive feedback loop involving the Wnt/I^-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. ( 27821172 )
2016
23
Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy. ( 26734914 )
2016
24
Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report. ( 27930548 )
2016
25
ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman. ( 27445489 )
2016
26
ALK-positive anaplastic large cell lymphoma: an evolving story. ( 25961700 )
2015
27
The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. ( 25797883 )
2015
28
Metachronous classical Hodgkin's lymphoma and ALK-positive anaplastic large cell lymphoma. ( 25938345 )
2015
29
Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis. ( 26508931 )
2015
30
ALK-positive anaplastic large cell lymphoma presenting with hemophagocytic lymphohistiocytosis. ( 26114236 )
2015
31
ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement. ( 25738071 )
2015
32
Intra-abdominal ALK-positive anaplastic large cell lymphoma in a patient with neurofibromatosis type 1. ( 26272700 )
2015
33
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 25421750 )
2015
34
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. ( 25921060 )
2015
35
Correction: Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma. ( 26420623 )
2015
36
MicroRNA and ALK-positive anaplastic large cell lymphoma. ( 25961697 )
2015
37
ALK-positive anaplastic large cell lymphoma with prominent bone involvement. ( 26018037 )
2015
38
Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. ( 26133723 )
2015
39
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. ( 26338968 )
2015
40
ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern. ( 25674293 )
2014
41
Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant. ( 25971833 )
2014
42
Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult. ( 24696735 )
2014
43
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24509625 )
2014
44
Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. ( 24297868 )
2014
45
Editor in Chief: Response to Eyre etA al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease" ( 24953081 )
2014
46
ALK Positive Anaplastic Large Cell Lymphoma With Pure Leptomeningeal Involvement: Unique Case Report and Review of the Literature. ( 24407988 )
2014
47
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 25855891 )
2014
48
Diagnosis of ALK-positive anaplastic large cell lymphoma based on CD30 testing. ( 24852617 )
2014
49
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma. ( 23975180 )
2014
50
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. ( 22820970 )
2013

Variations for Alk-Positive Anaplastic Large Cell Lymphoma

Expression for Alk-Positive Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Positive Anaplastic Large Cell Lymphoma.

Pathways for Alk-Positive Anaplastic Large Cell Lymphoma

Pathways related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 JAK3 MCL1 MUC1 STAT3
2
Show member pathways
12.37 ALK JAK3 STAT3
3
Show member pathways
12.27 JAK3 MCL1 STAT3
4
Show member pathways
12.17 JAK3 MCL1 STAT3
5 11.98 ALK JAK3 SHH STAT3
6
Show member pathways
11.86 JAK3 MCL1 STAT3
7
Show member pathways
11.47 MCL1 STAT3
8 11.29 MCL1 NPM1
9 11.11 ALK SHH
10
Show member pathways
11.07 JAK3 STAT3
11
Show member pathways
10.99 JAK3 STAT3
12 10.98 JAK3 MCL1 MUC1 STAT3
13 10.86 JAK3 STAT3
14 10.63 SHH STAT3

GO Terms for Alk-Positive Anaplastic Large Cell Lymphoma

Biological processes related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.61 ALK SHH STAT3
2 response to cytokine GO:0034097 9.46 MCL1 STAT3
3 interleukin-7-mediated signaling pathway GO:0038111 9.4 JAK3 STAT3
4 interleukin-15-mediated signaling pathway GO:0035723 9.37 JAK3 STAT3
5 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.32 JAK3 STAT3
6 interleukin-9-mediated signaling pathway GO:0038113 9.26 JAK3 STAT3
7 cytokine-mediated signaling pathway GO:0019221 9.26 JAK3 MCL1 MUC1 STAT3
8 interleukin-21-mediated signaling pathway GO:0038114 9.16 JAK3 STAT3
9 negative regulation of apoptotic process GO:0043066 9.02 ALK MCL1 NPM1 SHH STAT3

Molecular functions related to Alk-Positive Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.62 JAK3 STAT3

Sources for Alk-Positive Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....